Clovis Oncology's supplemental new drug application for Rubraca, or rucaparib, which is being developed as a maintenance treatment for female patients with recurrent, platinum-sensitive ovarian cancer with or without BRCA mutation, was granted priority review designation by the FDA. The agency's action date is April 6.
FDA priority review status given to Clovis' ovarian cancer drug
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.